{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:32:32Z","timestamp":1793971952831,"version":"4.8.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Genomics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>General transcription factor IIi (GTF2I) mutations are very common in thymic epithelial tumors (TETs) and are related to a more favorable prognosis in TET patients. However, limited research has been conducted on the role of GTF2I in the tumor immune microenvironment (TIME). Further, long non-coding RNAs (lncRNAs) have been associated with the survival of patients with TETs. Therefore, this study aimed to explore the relationship between GTF2I mutations and TIME and build a new potential signature for predicting tumor recurrence in the TETs. Research data was downloaded from The Cancer Genome Atlas database and the CIBERSORT algorithm was used to evaluate TIME differences between GTF2I mutant and wild-type TETs. Relevant differentially expressed lncRNAs based on differentially expressed immune-related genes were identified to establish lncRNA pairs. We constructed a signature using univariate and multivariate Cox regression analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>GTF2I is the most commonly mutated gene in TETs, and is associated with an increased number of early-stage pathological types, as well as no history of myasthenia gravis or radiotherapy treatment. In the GTF2I wild-type group, immune score and immune cell infiltrations with M2 macrophages, activated mast cells, neutrophils, plasma, T helper follicular cells, and activated memory CD4 T cells were higher than the GTF2I mutant group. A risk model was built using five lncRNA pairs, and the 1-, 3-, and 5-year area under the curves were 0.782, 0.873, and 0.895, respectively. A higher risk score was related to more advanced histologic type.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We can define the GTF2I mutant-type TET as an immune stable type and the GTF2I wild-type as an immune stressed type. A signature based on lncRNA pairs was also constructed to effectively predict tumor recurrence.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12864-022-08880-3","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T21:02:44Z","timestamp":1663362164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Thymic epithelial tumors: examining the GTF2I mutation and developing a novel prognostic signature with LncRNA pairs to predict tumor recurrence"],"prefix":"10.1186","volume":"23","author":[{"given":"Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Shuai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hao","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-He","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Yan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Fen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"issue":"10 Suppl 4","key":"8880_CR1","doi-asserted-by":"publisher","first-page":"S260","DOI":"10.1097\/JTO.0b013e3181f1f62d","volume":"5","author":"EA Engels","year":"2010","unstructured":"Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol. 2010;5(10 Suppl 4):S260\u20135.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"8880_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejca.2007.11.004","volume":"44","author":"WK de Jong","year":"2008","unstructured":"de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer. 2008;44(1):123\u201330.","journal-title":"Eur J Cancer"},{"issue":"2","key":"8880_CR3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jtho.2021.10.010","volume":"17","author":"A Marx","year":"2022","unstructured":"Marx A, Chan JKC, Chalabreysse L, Dacic S, Detterbeck F, French CA, et al. The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors? J Thorac Oncol. 2022;17(2):200\u201313.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"8880_CR4","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.athoracsur.2003.07.042","volume":"77","author":"K Kondo","year":"2004","unstructured":"Kondo K, Yoshizawa K, Tsuyuguchi M, Kimura S, Sumitomo M, Morita J, et al. WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg. 2004;77(4):1183\u20138.","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"8880_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ejcts.2004.04.041","volume":"26","author":"F Rea","year":"2004","unstructured":"Rea F, Marulli G, Girardi R, Bortolotti L, Favaretto A, Galligioni A, et al. Long-term survival and prognostic factors in thymic epithelial tumours. Eur J Cardiothorac Surg. 2004;26(2):412\u20138.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"5","key":"8880_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ctrv.2012.11.005","volume":"39","author":"A Lamarca","year":"2013","unstructured":"Lamarca A, Moreno V, Feliu J. Thymoma and thymic carcinoma in the target therapies era. Cancer Treat Rev. 2013;39(5):413\u201320.","journal-title":"Cancer Treat Rev"},{"issue":"10 Suppl 4","key":"8880_CR7","doi-asserted-by":"publisher","first-page":"S304","DOI":"10.1097\/JTO.0b013e3181f20c05","volume":"5","author":"A Masaoka","year":"2010","unstructured":"Masaoka A. Staging system of thymoma. J Thorac Oncol. 2010;5(10 Suppl 4):S304\u201312.","journal-title":"J Thorac Oncol"},{"key":"8880_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.lungcan.2017.05.020","volume":"110","author":"Y Feng","year":"2017","unstructured":"Feng Y, Lei Y, Wu X, Huang Y, Rao H, Zhang Y, et al. GTF2I mutation frequently occurs in more indolent thymic epithelial tumors and predicts better prognosis. Lung Cancer. 2017;110:48\u201352.","journal-title":"Lung Cancer"},{"issue":"8","key":"8880_CR9","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/ng.3016","volume":"46","author":"I Petrini","year":"2014","unstructured":"Petrini I, Meltzer PS, Kim IK, Lucchi M, Park KS, Fontanini G, et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet. 2014;46(8):844\u20139.","journal-title":"Nat Genet"},{"issue":"18","key":"8880_CR10","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557\u201366.","journal-title":"Cancer Res"},{"issue":"8","key":"8880_CR11","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","volume":"27","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482\u201392.","journal-title":"Ann Oncol"},{"issue":"5","key":"8880_CR12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","volume":"54","author":"AJ Ozga","year":"2021","unstructured":"Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity. 2021;54(5):859\u201374.","journal-title":"Immunity"},{"issue":"15","key":"8880_CR13","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1158\/0008-5472.CAN-16-2634","volume":"77","author":"A Bhan","year":"2017","unstructured":"Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965\u201381.","journal-title":"Cancer Res"},{"key":"8880_CR14","doi-asserted-by":"crossref","unstructured":"Chi Y, Wang D, Wang J, Yu W, Yang J. Long Non-Coding RNA in the Pathogenesis of Cancers. Cells. 2019;8(9):1015.","DOI":"10.3390\/cells8091015"},{"issue":"9","key":"8880_CR15","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1093\/nar\/gkt182","volume":"41","author":"Q Liu","year":"2013","unstructured":"Liu Q, Huang J, Zhou N, Zhang Z, Zhang A, Lu Z, et al. LncRNA loc285194 is a p53-regulated tumor suppressor. Nucleic Acids Res. 2013;41(9):4976\u201387.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"8880_CR16","doi-asserted-by":"publisher","first-page":"7349","DOI":"10.1038\/s41467-021-26901-9","volume":"12","author":"N Singh","year":"2021","unstructured":"Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, et al. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021;12(1):7349.","journal-title":"Nat Commun"},{"key":"8880_CR17","doi-asserted-by":"crossref","unstructured":"Wang J, Huang H, Zhang X, Ma H. LOXL1\u2011AS1 promotes thymoma and thymic carcinomaprogression by regulating miR\u2011525\u20115p\u2011HSPA9. Oncol Rep. 2021;45(6):117.","DOI":"10.3892\/or.2021.8068"},{"issue":"11","key":"8880_CR18","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/s41419-020-03171-9","volume":"11","author":"C Tito","year":"2020","unstructured":"Tito C, Ganci F, Sacconi A, Masciarelli S, Fontemaggi G, Pulito C, et al. LINC00174 is a novel prognostic factor in thymic epithelial tumors involved in cell migration and lipid metabolism. Cell Death Dis. 2020;11(11):959.","journal-title":"Cell Death Dis"},{"issue":"1","key":"8880_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12886","volume":"92","author":"B Hu","year":"2020","unstructured":"Hu B, Niu L, Jiang Z, Xu S, Hu Y, Cao K. LncRNA XLOC_003810 promotes T cell activation and inhibits PD-1\/PD-L1 expression in patients with myasthenia gravis-related thymoma. Scand J Immunol. 2020;92(1):e12886.","journal-title":"Scand J Immunol"},{"key":"8880_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.666155","volume":"12","author":"J Shao","year":"2021","unstructured":"Shao J, Lyu W, Zhou J, Xu W, Wang D, Liang S, et al. A panel of five-lncRNA signature as a potential biomarker for predicting survival in gastric and thoracic cancers. Front Genet. 2021;12:666155.","journal-title":"Front Genet"},{"issue":"7","key":"8880_CR21","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/1759-7714.13439","volume":"11","author":"Y Su","year":"2020","unstructured":"Su Y, Chen Y, Tian Z, Lu C, Chen L, Ma X. lncRNAs classifier to accurately predict the recurrence of thymic epithelial tumors. Thorac Cancer. 2020;11(7):1773\u201383.","journal-title":"Thorac Cancer"},{"key":"8880_CR22","first-page":"1031906","volume":"2021","author":"R Zhou","year":"2021","unstructured":"Zhou R, Liang J, Tian H, Chen Q, Yang C, Liu C. Development of a Ferroptosis-related lncRNA signature to predict the prognosis and immune landscape of bladder cancer. Dis Markers. 2021;2021:1031906.","journal-title":"Dis Markers"},{"issue":"11","key":"8880_CR23","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/jamaoncol.2017.1609","volume":"3","author":"B Li","year":"2017","unstructured":"Li B, Cui Y, Diehn M, Li R. Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol. 2017;3(11):1529\u201337.","journal-title":"JAMA Oncol"},{"issue":"10","key":"8880_CR24","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1080\/14737140.2021.1962297","volume":"21","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang X, Dai X, He D. Applying immune-related lncRNA pairs to construct a prognostic signature and predict the immune landscape of stomach adenocarcinoma. Expert Rev Anticancer Ther. 2021;21(10):1161\u201370.","journal-title":"Expert Rev Anticancer Ther"},{"key":"8880_CR25","doi-asserted-by":"publisher","first-page":"1609858","DOI":"10.3389\/pore.2021.1609858","volume":"27","author":"D Jain","year":"2021","unstructured":"Jain D, Guleria P, Singh V, Parshad R, Kumar S, Gaiser T, et al. GTF2I mutation in Thymomas: Independence from racial-ethnic backgrounds. An Indian\/German comparative study. Pathol Oncol Res. 2021;27:1609858.","journal-title":"Pathol Oncol Res"},{"key":"8880_CR26","doi-asserted-by":"crossref","unstructured":"Wells K, Lamrca A, Papaxoinis G, Wallace A, Quinn AM, Summers Y, et al. Unique correlation between GTF2I mutation and spindle cell morphology in thymomas (type A and AB thymomas). J Clin Pathol. 2021;20(7):837.","DOI":"10.1136\/jclinpath-2021-207837"},{"issue":"1","key":"8880_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12943-020-01170-0","volume":"19","author":"B Zhang","year":"2020","unstructured":"Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL. m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol Cancer. 2020;19(1):53.","journal-title":"Mol Cancer"},{"issue":"1","key":"8880_CR28","doi-asserted-by":"publisher","first-page":"5499","DOI":"10.1038\/s41467-019-13329-5","volume":"10","author":"X Tekpli","year":"2019","unstructured":"Tekpli X, Lien T, R\u00f8ssevold AH, Nebdal D, Borgen E, Ohnstad HO, et al. An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment. Nat Commun. 2019;10(1):5499.","journal-title":"Nat Commun"},{"issue":"1","key":"8880_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12943-019-1062-7","volume":"18","author":"A Lin","year":"2019","unstructured":"Lin A, Wei T, Meng H, Luo P, Zhang J. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Mol Cancer. 2019;18(1):139.","journal-title":"Mol Cancer"},{"key":"8880_CR30","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3389\/fonc.2020.01478","volume":"10","author":"A Cafaro","year":"2020","unstructured":"Cafaro A, Bongiovanni A, Di Iorio V, Oboldi D, Masini C, Ibrahim T. Pembrolizumab in a patient with heavily pre-treated squamous cell Thymic carcinoma and cardiac impairment: a case report and literature review. Front Oncol. 2020;10:1478.","journal-title":"Front Oncol"},{"key":"8880_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.621858","volume":"12","author":"L Shen","year":"2021","unstructured":"Shen L, Chen H, Wei Q. Immune-therapy-related toxicity events and dramatic remission after a single dose of pembrolizumab treatment in metastatic thymoma: a case report. Front Immunol. 2021;12:621858.","journal-title":"Front Immunol"},{"issue":"1","key":"8880_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","volume":"7","author":"A Rajan","year":"2019","unstructured":"Rajan A, Heery CR, Thomas A, Mammen AL, Perry S, O'Sullivan Coyne G, et al. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. J Immunother Cancer. 2019;7(1):269.","journal-title":"J Immunother Cancer"},{"key":"8880_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.lungcan.2019.06.015","volume":"135","author":"T Konstantina","year":"2019","unstructured":"Konstantina T, Konstantinos R, Anastasios K, Anastasia M, Eleni L, Ioannis S, et al. Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review. Lung Cancer. 2019;135:29\u201332.","journal-title":"Lung Cancer"},{"issue":"9","key":"8880_CR34","doi-asserted-by":"publisher","first-page":"10083","DOI":"10.21037\/apm-21-943","volume":"10","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Li W, Hu X, Zhang J. A case report of advanced thymoma re-treated with PD-1 inhibitor after initial immune-related pneumonitis. Ann Palliat Med. 2021;10(9):10083\u201390.","journal-title":"Ann Palliat Med"},{"issue":"4","key":"8880_CR35","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.21037\/cdt-21-147","volume":"11","author":"A Portol\u00e9s Hern\u00e1ndez","year":"2021","unstructured":"Portol\u00e9s Hern\u00e1ndez A, Blanco Clemente M, Escribano Garc\u00eda D, Velasco Calvo R, N\u00fa\u00f1ez Garc\u00eda B, Oteo Dom\u00ednguez JF, et al. Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia gravis-a case report. Cardiovasc Diagn Ther. 2021;11(4):1013\u20139.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"4","key":"8880_CR36","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ccell.2018.07.009","volume":"34","author":"O Meurette","year":"2018","unstructured":"Meurette O, Mehlen P. Notch signaling in the tumor microenvironment. Cancer Cell. 2018;34(4):536\u201348.","journal-title":"Cancer Cell"},{"key":"8880_CR37","doi-asserted-by":"crossref","unstructured":"Itatani Y, Kawada K, Sakai Y. Transforming growth factor\u2011\u03b2 signaling pathway in colorectal cancer and its tumor microenvironment. Int J Mol Sci.2019;20(23):5822.","DOI":"10.3390\/ijms20235822"},{"key":"8880_CR38","doi-asserted-by":"crossref","unstructured":"Wang K, Qiu X, Zhao Y, Wang H, Chen L. The Wnt\/\u03b2\u2011catenin signaling pathway in the tumor microenvironment of hepatocellular carcinoma. Cancer Biol Med. 2021;19(3):305\u201318.","DOI":"10.20892\/j.issn.2095-3941.2021.0306"},{"key":"8880_CR39","unstructured":"Taciak B, Pruszynska I, Kiraga L, Bialasek M, Krol M. Wnt signaling pathway in development and cancer. J Physiol Pharmacol. 2018;69(2):185\u201396."},{"issue":"1","key":"8880_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","volume":"3","author":"S Colak","year":"2017","unstructured":"Colak S, Ten Dijke P. Targeting TGF-\u03b2 signaling in cancer. Trends Cancer. 2017;3(1):56\u201371.","journal-title":"Trends Cancer"},{"key":"8880_CR41","doi-asserted-by":"crossref","unstructured":"Tyagi A, Sharma AK, Damodaran C. A review on notch signaling and colorectal cancer. Cells. 2020;9(6):1549.","DOI":"10.3390\/cells9061549"},{"issue":"1","key":"8880_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12943-020-01206-5","volume":"19","author":"Y Liang","year":"2020","unstructured":"Liang Y, Song X, Li Y, Chen B, Zhao W, Wang L, et al. LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303\/PTBP3 axis. Mol Cancer. 2020;19(1):85.","journal-title":"Mol Cancer"},{"issue":"1","key":"8880_CR43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-020-01277-4","volume":"19","author":"K Shigeyasu","year":"2020","unstructured":"Shigeyasu K, Toden S, Ozawa T, Matsuyama T, Nagasaka T, Ishikawa T, et al. The PVT1 lncRNA is a novel epigenetic enhancer of MYC, and a promising risk-stratification biomarker in colorectal cancer. Mol Cancer. 2020;19(1):155.","journal-title":"Mol Cancer"},{"issue":"1","key":"8880_CR44","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12943-019-1013-3","volume":"18","author":"X Wang","year":"2019","unstructured":"Wang X, Yang J, Guo G, Feng R, Chen K, Liao Y, et al. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway. Mol Cancer. 2019;18(1):84.","journal-title":"Mol Cancer"},{"issue":"1","key":"8880_CR45","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41467-022-28421-6","volume":"13","author":"Z Liu","year":"2022","unstructured":"Liu Z, Liu L, Weng S, Guo C, Dang Q, Xu H, et al. Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer. Nat Commun. 2022;13(1):816.","journal-title":"Nat Commun"},{"key":"8880_CR46","doi-asserted-by":"crossref","unstructured":"Zhu H, Liu Q, Yang X, Ding C, Wang Q, Xiong Y. LncRNA LINC00649 recruits TAF15 and enhances MAPK6 expression to promote the development of lung squamous cell carcinoma via activating MAPK signaling pathway. Cancer Gene Ther. 2022;29(8-9):1285\u201395.","DOI":"10.1038\/s41417-021-00410-9"},{"issue":"12","key":"8880_CR47","doi-asserted-by":"publisher","first-page":"19673","DOI":"10.1002\/jcb.29273","volume":"120","author":"F Chen","year":"2019","unstructured":"Chen F, Li Z, Deng C, Yan H. Integrated analysis identifying new lncRNA markers revealed in ceRNA network for tumor recurrence in papillary thyroid carcinoma and build of nomogram. J Cell Biochem. 2019;120(12):19673\u201383.","journal-title":"J Cell Biochem"},{"key":"8880_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.754503","volume":"12","author":"S Cheng","year":"2021","unstructured":"Cheng S, Guo J, Wang D, Fang Q, Liu Y, Xie W, et al. A novel three-LncRNA signature predicting tumor recurrence in nonfunctioning pituitary adenomas. Front Genet. 2021;12:754503.","journal-title":"Front Genet"},{"issue":"3","key":"8880_CR49","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/1759-7714.13325","volume":"11","author":"X Zhang","year":"2020","unstructured":"Zhang X, Han J, Du L, Li X, Hao J, Wang L, et al. Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma. Thorac Cancer. 2020;11(3):728\u201337.","journal-title":"Thorac Cancer"},{"issue":"7","key":"8880_CR50","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41419-020-02740-2","volume":"11","author":"H Fan","year":"2020","unstructured":"Fan H, Ge Y, Ma X, Li Z, Shi L, Lin L, et al. Long non-coding RNA CCDC144NL-AS1 sponges miR-143-3p and regulates MAP3K7 by acting as a competing endogenous RNA in gastric cancer. Cell Death Dis. 2020;11(7):521.","journal-title":"Cell Death Dis"},{"issue":"10","key":"8880_CR51","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s12033-021-00351-6","volume":"63","author":"L Zhang","year":"2021","unstructured":"Zhang L, Chi B, Chai J, Qin L, Zhang G, Hua P, et al. LncRNA CCDC144NL-AS1 serves as a prognosis biomarker for non-small cell lung cancer and promotes cellular function by targeting miR-490-3p. Mol Biotechnol. 2021;63(10):933\u201340.","journal-title":"Mol Biotechnol"},{"key":"8880_CR52","doi-asserted-by":"crossref","unstructured":"Tan Y, Xu F, Xu L, Cui J. Long non\u2011coding RNA LINC01748 exerts carcinogenic effects in non\u2011small cell lung cancer cell lines by regulating the microRNA\u2011520a\u20115p\/HMGA1 axis. Int J Mol Med. 2022;49(2):22.","DOI":"10.3892\/ijmm.2021.5077"},{"issue":"5","key":"8880_CR53","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137.","journal-title":"Nat Methods"},{"key":"8880_CR54","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"issue":"22","key":"8880_CR55","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1001\/jama.291.22.2727","volume":"291","author":"KA Eagle","year":"2004","unstructured":"Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. Jama. 2004;291(22):2727\u201333.","journal-title":"Jama"},{"issue":"10","key":"8880_CR56","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28217","volume":"4","author":"JX Lin","year":"2021","unstructured":"Lin JX, Wang ZK, Hong QQ, Zhang P, Zhang ZZ, He L, et al. Assessment of clinicopathological characteristics and development of an individualized prognostic model for patients with Hepatoid adenocarcinoma of the stomach. JAMA Netw Open. 2021;4(10):e2128217.","journal-title":"JAMA Netw Open"}],"container-title":["BMC Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12864-022-08880-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12864-022-08880-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12864-022-08880-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T22:04:51Z","timestamp":1663365891000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgenomics.biomedcentral.com\/articles\/10.1186\/s12864-022-08880-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8880"],"URL":"https:\/\/doi.org\/10.1186\/s12864-022-08880-3","relation":{},"ISSN":["1471-2164"],"issn-type":[{"value":"1471-2164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]},"assertion":[{"value":"12 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods in this research were carried out in accordance with relevant guidelines and regulations of The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Data of our present study was downloaded from the publicly available dataset TCGA, so our study did not require approval from an ethics committee and did not involve human or animal subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no conflicts of interest regarding the publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"656"}}